ISPOR - PND44 Cost-Utility Analysis and Cost-Minimisation Analysis of Sabril® (Vigabatrin) in Drug-Resistant Epilepsy From Payer's Perspective in Poland

Full Text

PND44 Cost-Utility Analysis and Cost-Minimisation Analysis of Sabril® (Vigabatrin) in Drug-Resistant Epilepsy From Payer's Perspective in Poland

Abstract

Authors

P. Kawalec P. Holko J. Lis M. Glasek

Back to Volume 15, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now